Standard
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. / Giovannoni, Gavin; Comi, Giancarlo; Cook, Stuart; Rammohan, Kottil; Rieckmann, Peter; Soelberg Sørensen, Per; Vermersch, Patrick; Chang, Peter; Hamlett, Anthony; Musch, Bruno; Greenberg, Steven J; CLARITY study group.
In:
New England Journal of Medicine, Vol. 362, No. 5, 04.02.2010, p. 416-26.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Giovannoni, G, Comi, G, Cook, S, Rammohan, K, Rieckmann, P
, Soelberg Sørensen, P, Vermersch, P, Chang, P, Hamlett, A, Musch, B, Greenberg, SJ & CLARITY study group 2010, '
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis',
New England Journal of Medicine, vol. 362, no. 5, pp. 416-26.
https://doi.org/10.1056/NEJMoa0902533APA
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P.
, Soelberg Sørensen, P., Vermersch, P., Chang, P., Hamlett, A., Musch, B., Greenberg, S. J., & CLARITY study group (2010).
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
New England Journal of Medicine,
362(5), 416-26.
https://doi.org/10.1056/NEJMoa0902533Vancouver
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P
, Soelberg Sørensen P et al.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
New England Journal of Medicine. 2010 Feb 4;362(5):416-26.
https://doi.org/10.1056/NEJMoa0902533Author
Giovannoni, Gavin ; Comi, Giancarlo ; Cook, Stuart ; Rammohan, Kottil ; Rieckmann, Peter ; Soelberg Sørensen, Per ; Vermersch, Patrick ; Chang, Peter ; Hamlett, Anthony ; Musch, Bruno ; Greenberg, Steven J ; CLARITY study group. / A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. In: New England Journal of Medicine. 2010 ; Vol. 362, No. 5. pp. 416-26.
Bibtex
@article{8ab122da9d49401fa3967ead6ad03d08,
title = "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis",
abstract = "Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.",
author = "Gavin Giovannoni and Giancarlo Comi and Stuart Cook and Kottil Rammohan and Peter Rieckmann and {Soelberg S{\o}rensen}, Per and Patrick Vermersch and Peter Chang and Anthony Hamlett and Bruno Musch and Greenberg, {Steven J} and S{\o}rensen, {Per Soelberg}",
note = "2010 Massachusetts Medical Society",
year = "2010",
month = feb,
day = "4",
doi = "http://dx.doi.org/10.1056/NEJMoa0902533",
language = "English",
volume = "362",
pages = "416--26",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "5",
}
RIS
TY - JOUR
T1 - A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
AU - Giovannoni, Gavin
AU - Comi, Giancarlo
AU - Cook, Stuart
AU - Rammohan, Kottil
AU - Rieckmann, Peter
AU - Soelberg Sørensen, Per
AU - Vermersch, Patrick
AU - Chang, Peter
AU - Hamlett, Anthony
AU - Musch, Bruno
AU - Greenberg, Steven J
AU - CLARITY study group
N1 - 2010 Massachusetts Medical Society
PY - 2010/2/4
Y1 - 2010/2/4
N2 - Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.
AB - Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.
U2 - http://dx.doi.org/10.1056/NEJMoa0902533
DO - http://dx.doi.org/10.1056/NEJMoa0902533
M3 - Journal article
VL - 362
SP - 416
EP - 426
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 5
ER -
